NH TherAguix, a French clinical biotech specialized in the development of innovative nanomedicines for the treatment of cancer by radiotherapy, announces today the arrival of Aurélien Meyzaud as Head of Intellectual Property and Business Intelligence from January 2.
NH TherAguix annonce le lancement de la campagne de communication par la société Pivotal, pour aider au recrutement de patients dans l’étude NANORAD2 dont le promoteur est le CHU Grenoble Alpes.
NH TherAguix is pleased and proud to announce that Mr Paul Rocchi successfully defended his thesis, as the first CIFRE PhD student of the company – Oct. 06, 2022.
NH TherAguix (“NHT”), announces today the arrival of Dr. Olivier de Beaumont as Chief Medical Officer from September 2022. – Sept. 09, 2022.
NH TherAguix et le Centre de Lutte Contre le Cancer Jean PERRIN de Clermont-Ferrand annoncent le recrutement du premier patient de l’étude de phase I/II Nano-GBM ciblant les glioblastomes nouvellement diagnostiqués, étude promue par le Centre Jean PERRIN et dirigée par le Dr Julian Biau, oncologue-radiothérapeute – Grenoble et Clermont-Ferrand (France) – May 13, 2022.
Meylan (France) and Boston (US), October 1st, 2021 – NH TherAguix announces the enrolment of the 2 first patients in its clinical trials NANOBRAINMETS Phase II targeting brain metastasis and NANOSMART Phase Ib/II targeting pancreatic cancer and cancerous lung lesions.
Grenoble (France), 28 September 2021 NH TherAguix, French biotech company specialized in the development of innovative nanomedicines for the treatment of cancer by radiotherapy, today announces the launch of its initial public offering with a view to listing its shares on the Euronext Growth market (ISIN code: FR0013105954 – ticket: ALNHT).
Grenoble (France), 13 September 2021 NH TherAguix, French biotech company specialized in the development of innovative nanomedicines for the treatment of cancer by radiotherapy, today announces the approval of its registration document by the Autorité des marchés financiers (the “AMF”) under number I.21-048 dated 10 September 2021.
NH TherAguix is pleased to announce that Fabien Boux which joined the Clinical Development Unit as Biomedical Engineer in January, was awarded with the Ph. D. prize 2020 of the Société Française de Résonance Magnétique en Biologie et Médecine (“SFRMBM”).
NH TherAguix and the CHU Grenoble-Alpes announce the publication of the results of the First-In-Human phase 1 clinical trial on the combination of AGuIX with radiotherapy on multiple brain metastases patients – Grenoble (France), May 31, 2021 – 11:00 pm (CET)
NH TherAguix, a start-up specializing in nanomedicine for cancer radiotherapy, announces a €13 million round of fundraising, led by Bpifrance – Grenoble/Lyon/Paris (France) – 11 April 2019
Sanofi and Lyon start-up NH TherAguix team up to produce AGuIX®, an innovative nanoparticle in oncology – Paris (France) – February, 18, 2019